Immune Response to Ovarian and other gynaecological Cancers (IROC) Biobank, Canada

Registration Status: Completed

Objective: Immune Response to Ovarian and other gynecological Cancers (IROC) biobank is leading to a better understanding of the immune response to ovarian cancer and other gynecological cancers. The findings from this study are helping us design new immune-based treatments for these diseases.

Registered Biobank Name	Immune Response to Ovarian and other gynaecological Cancers (IROC) Biobank
Biobank Leader	Brad Nelson
Country	Canada
Email for biobank inquiries	david.bond@bccancer.bc.ca
Principal Investigator	Brad Nelson
Website	http://www.bccrc.ca/dept/iroc
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Oligo - Collection aimed at supporting several research projects, a research group or a research consortium

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).